Journals / Medeniyet Medical Journal / 2020 / Cilt: 35 - Sayı: 1

Efficacy and Safety of Intranasal Medical Management in Pediatric Patients with Idiopathic Recurrent Epistaxis

İdiyopatik Rekürren Epistaksisli Pediyatrik Hastalarda İntranazal Medikal Tedavinin Etkinliği ve Güvenliği

Pages
1–7
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Recurrence ofepistaxis was seen in 22.9% (8/35) of hyperemic nasal mucosa group and in 34.4% (11/32) ofhypervascular nasal mucosa group (p>0.05).Conclusion: We advise the use of both an intranasal antimicrobial ointment and a mucosalmoisturizing gel as an effective, noninvasive and easily applicable medical treatment option forpediatric patients with idiopathic recurrent epistaxis before more invasive methods of epistaxiscontrol.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The goal of the study was to verify the efficacy and safety of topical medical treatmentin idiopathic recurrent pediatric epistaxis patients by intranasal usage of both an antimicrobialand a moisturizing agent as a first-step management modality.Method: Sixty-seven out of 326 pediatric patients with idiopathic recurrent epistaxis selected ona chart review of follow-up were enrolled in the study.
📊
Key Findings & Data:The study was designed as an analysis oftwo groups: one group included 35 individuals (52.2% of the total cohort) having a hyperemicnasal mucosa and the second group included 32 individuals (47.8% of the total cohort) having ahypervascular nasal mucosa on physical examination before treatment.Results: The study was performed with a total of 67 children (age range 3-17 years) including36 males (53.7% of total cohort) and 31 females (46.3% of total cohort).
💡
Conclusion & Impact:Recurrence ofepistaxis was seen in 22.9% (8/35) of hyperemic nasal mucosa group and in 34.4% (11/32) ofhypervascular nasal mucosa group (p>0.05).Conclusion: We advise the use of both an intranasal antimicrobial ointment and a mucosalmoisturizing gel as an effective, noninvasive and easily applicable medical treatment option forpediatric patients with idiopathic recurrent epistaxis before more invasive methods of epistaxiscontrol.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The goal of the study was to verify the efficacy and safety of topical medical treatmentin idiopathic recurrent pediatric epistaxis patients by intranasal usage of both an antimicrobialand a moisturizing agent as a first-step management modality.Method: Sixty-seven out of 326 pediatric patients with idiopathic recurrent epistaxis selected ona chart review of follow-up were enrolled in the study. The study was designed as an analysis oftwo groups: one group included 35 individuals (52.2% of the total cohort) having a hyperemicnasal mucosa and the second group included 32 individuals (47.8% of the total cohort) having ahypervascular nasal mucosa on physical examination before treatment.Results: The study was performed with a total of 67 children (age range 3-17 years) including36 males (53.7% of total cohort) and 31 females (46.3% of total cohort). The mean age was9.78±4.09 years. There was not any statistically significant difference between the groups interms of age, duration of follow-up and recurrence time of epistaxis (p>0.05). Recurrence ofepistaxis was seen in 22.9% (8/35) of hyperemic nasal mucosa group and in 34.4% (11/32) ofhypervascular nasal mucosa group (p>0.05).Conclusion: We advise the use of both an intranasal antimicrobial ointment and a mucosalmoisturizing gel as an effective, noninvasive and easily applicable medical treatment option forpediatric patients with idiopathic recurrent epistaxis before more invasive methods of epistaxiscontrol.

Özet

Amaç: Çalışmanın amacı, idiyopatik rekürren pediyatrik epistaksis hastalarında topikal tıbbi tedavinin etkinliğini ve güvenliğini hem antimikrobiyal hem de nemlendirici bir ajanın intranazal uygulanmasının birinci basamak tedavi yöntemi olarak incelemektir. Yöntem: İzlemin hasta kayıtlarının gözden geçirilmesiyle seçilen idiyopatik tekrarlayan burun kanaması olan 326 pediyatrik hastanın 67’si çalışmaya dahil edildi. Çalışma iki grubun analizi olarak tasarlanmıştır: bir grupta hiperemik burun mukozasına sahip 35 pediyatrik hasta (toplam kohortun %52,2’si) ve ikinci grupta hipervasküler burun mukozasına sahip 32 pediyatrik hasta (toplam kohortun %47,8’i) tedaviden önce fizik muayeneleri yapılmış uygun hastalar olarak seçilmiştir. Bulgular: Çalışma 36 erkek (toplam kohortun %53,7’si) ve 31 kadın (toplam kohortun %46,3’ü) olmak üzere toplam 67 çocuk hasta (3-17 yaş arası) ile gerçekleştirildi. Yaş ortalaması 9,78±4,09 idi. Gruplar arasında yaş, takip süresi ve burun kanaması nüks süresi açısından istatistiksel olarak anlamlı fark yoktu (p>0,05). Hiperemik nazal mukoza grubunun %22,9’unda (8/35) ve hipervasküler nazal mukoza grubunun %34,4’ünde (11/32) burun kanaması nüksü görüldü (p>0,05). Sonuç: Daha invaziv epistaksis kontrol yöntemlerinden önce, idiyopatik tekrarlayan epistaksisi olan pediyatrik hastalar için hem intranazal antimikrobiyal merhem hem de mukozal nemlendirici jelin birlikte kullanımının etkili, invaziv olmayan ve kolayca uygulanabilir bir tıbbi tedavi seçeneği olarak kullanılmasını öneriyoruz.

🔖

Cite This Article

OZDAMAR, O. I., ACAR, G. Ö. (2022). Efficacy and Safety of Intranasal Medical Management in Pediatric Patients with Idiopathic Recurrent Epistaxis. Medeniyet Medical Journal, Cilt: 35 - Sayı: 1, 1–7. https://ajindex.com/articles/579221

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Booth C, McMains K. Pediatric epistaxis. In: Pediatric otolaryngology for the Clinician. Mitchell and K.D. Pereira (eds.), Humana Press, a part of Springer Science, Business Media, LLC, 2009, p:97. [CrossRef] 2. Saafan ME, Ibrahim WS. Role of bacterial biofilms in idiopathic childhood epistaxis. Eur Arch Otorhinolaryngol. 2013
  2. [CrossRef] 3. Béquignon E, Teissier N, Gauthier A, Brugel L, De Kermadec H, Coste A, Prulière-Escabasse V. Emergency department care of childhood epistaxis. Emerg Med J. 2017
  3. [CrossRef] 4. Glynn F, Amin M, Sheahan P, Mc Shane D. Prospective double blind randomized clinical trial comparing 75% versus 95% silver nitrate cauterization in the management of idiopathic childhood epistaxis. Int J Pediatr Otorhinolaryngol. 2011
  4. [CrossRef] 5. Ruddy J, Proops DW, Pearman K, et al. Management of epistaxis in children. Int J Pediatr Otorhinolaryngol. 1991
  5. [CrossRef] 6. Loughran S, Spinou E, Clement WA, et al. A prospective, single-blind, randomised controlled trial of petroleum jelly/Vaseline for recurrent paediatric epistaxis. Clin Otolaryngol. 2004
  6. [CrossRef] 7. Kubba H, MacAndie C, Botma M, et al. A prospective, single-blind, randomized controlled trial of antiseptic cream for recurrent epistaxis in childhood. Clin Otolaryngol Allied Sci. 2001
  7. [CrossRef] 8. Kamble P, Saxena S, Kumar S. Nasal bacterial colonization in cases of idiopathic epistaxis in children. Int J Pediatr Otorhinolaryngol. 2015
  8. [CrossRef] 9. Patel N, Maddalozzo J, Billings KR. An update on management of pediatric epistaxis. Int J Pediatr Otorhinolaryngol. 2014
  9. [CrossRef] 10. Elden L, Reinders M, Witmer C. Predictors of bleeding disorders in children with epistaxis: value of preoperative tests and clinical screenings. Int J Pediatr Otorhinolaryngol. 2012
  10. [CrossRef] 11. Whymark AD, Crampsey DP, Fraser L et al. Childhood epistaxis and nasal colonization with Staphylococcus aureus. Otolaryngol Head Neck Surg. 2008
  11. [CrossRef] 12. Korkmaz M, Cetinkol Y, Korkmaz H, et al. Nasal Bacterial Colonization in Pediatric Epistaxis: The Role of Topical Antibacterial Treatment. Balkan Med J. 2016
  12. [CrossRef] 13. Kamble P, Saxena S, Kumar S. Nasal bacterial colonization in cases of idiopathic epistaxis in children. Int J Pediatr Otorhinolaryngol. 2015
  13. [CrossRef] 14. Murthy P, Nilssen EL, Rao S, et al. A randomised clinical trial of antiseptic nasal carrier cream